systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-308Research ArticleКАРДИОНЕВРОЛОГИЯCовременные представления об идеальной комбинации антигипертензивных препаратов для профилактики инсультаОстроумоваО. Д.ostroumova.olga@mail.ruФоминаВ. М.noemail@neicon.ruГусеваТ. Ф.noemail@neicon.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России; ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииRussian FederationГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииRussian Federation2013231220221037176Copyright © Остроумова О.Д., Фомина В.М., Гусева Т.Ф., 20222022Остроумова О.Д., Фомина В.М., Гусева Т.Ф.Остроумова О.Д., Фомина В.М., Гусева Т.Ф.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/308

Статья посвящена выбору антигипертензивного препарата для профилактики инсульта. Подробно рассмотрены преимущества и механизмы церебропротективного действия лозартана и амлодипина. Приведены данные большого количества исследований, доказывающие эффективность данных препаратов в профилактике цереброваскулярных осложнений.

артериальная гипертонияинсультантигипертензивная терапияантагонисты рецепторов к ангиотензину IIлозартанантагонисты кальцияамлодипинфиксированные комбинации антигипертензивных препаратовReferencesСмертность населения Российской Федерации, 1998 г. (статистические материалы). М.: Минздрав РФ, 2006.Смертность населения Российской Федерации, 1998 г. (статистические материалы). М.: Минздрав РФ, 2006.Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журн. неврологии и психиатрии. 2007; 8: 4–10.Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журн. неврологии и психиатрии. 2007; 8: 4–10.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.Lewington S, Clarke R, Qizilbash N et al. Prospective Studies Collaboration. Age - specific relevance of usual blood pressure to vascular mortality: a meta - analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.Lewington S, Clarke R, Qizilbash N et al. Prospective Studies Collaboration. Age - specific relevance of usual blood pressure to vascular mortality: a meta - analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.Staessen J.A, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–76.Staessen J.A, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–76.Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin - converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta - analysis. J Hypertens 2008; 26 (7): 1282–9.Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin - converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta - analysis. J Hypertens 2008; 26 (7): 1282–9.Dahlöf B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995–1003.Dahlöf B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995–1003.Dahlöf B, Devereux R.B, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Am J Hypertens 1997; 10: 705–13.Dahlöf B, Devereux R.B, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Am J Hypertens 1997; 10: 705–13.Verdecchia P Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039–44.Verdecchia P Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039–44.Верещагин Н.В. Гетерогенность инсульта в клинической практике. Атмосфера. Нервные болезни. 2004; 1: 19–20.Верещагин Н.В. Гетерогенность инсульта в клинической практике. Атмосфера. Нервные болезни. 2004; 1: 19–20.Dempsey R.J, Diana A.L, Moore R.W. Thickness of carotid artery atherosclerotic plaque and ischemic risk. Neurosurgery 1990; 27 (3): 343–8.Dempsey R.J, Diana A.L, Moore R.W. Thickness of carotid artery atherosclerotic plaque and ischemic risk. Neurosurgery 1990; 27 (3): 343–8.Olsen M.H, Wachtell K, Neland K et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14: 177–83.Olsen M.H, Wachtell K, Neland K et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14: 177–83.Sonoda M, Aoyagi T, Takenaka K et al. A One-Year Study of the Antiatherosclerotic Effect of the Angiotensin-II Receptor Blocker Losartan in Hypertensive Patients (A Comparison With Angiotensin-Converting Enzyme Inhibitors). Int Heart J 2008; 49 (1): 95–103.Sonoda M, Aoyagi T, Takenaka K et al. A One-Year Study of the Antiatherosclerotic Effect of the Angiotensin-II Receptor Blocker Losartan in Hypertensive Patients (A Comparison With Angiotensin-Converting Enzyme Inhibitors). Int Heart J 2008; 49 (1): 95–103.Strawn W.B, Chappell M.C, Dean R.H et al. Inhibition of early atherogenesis by losartan in monkeys with diet - induced hypercholesterolemia. Circulation 2000; 101: 1586–93.Strawn W.B, Chappell M.C, Dean R.H et al. Inhibition of early atherogenesis by losartan in monkeys with diet - induced hypercholesterolemia. Circulation 2000; 101: 1586–93.Schiffrin E.L, Park J.B, Intengan H.D et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653–9.Schiffrin E.L, Park J.B, Intengan H.D et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653–9.Prasad A, Tupas-Habib T, Schenke W.H et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349–54.Prasad A, Tupas-Habib T, Schenke W.H et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349–54.Cheetham C, Collis J, O’Driscoll G et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non - insulin - dependent diabetes. J Am Coll Cardiol 2000; 36 (5): 1461–6.Cheetham C, Collis J, O’Driscoll G et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non - insulin - dependent diabetes. J Am Coll Cardiol 2000; 36 (5): 1461–6.Hornig B, Landmesser U, Kohler C et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001; 103: 799–805.Hornig B, Landmesser U, Kohler C et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001; 103: 799–805.Guerra-Cuesta J.I, Montón M, Rodriguez-Feo J.A et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447–52.Guerra-Cuesta J.I, Montón M, Rodriguez-Feo J.A et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447–52.Erdem Y, Usalan C, Haznedaroğlu I.C et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 11: 1071–6.Erdem Y, Usalan C, Haznedaroğlu I.C et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 11: 1071–6.Levy P.J, Yunis C, Owen J et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86: 1188–92.Levy P.J, Yunis C, Owen J et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86: 1188–92.Fogari R, Zoppi A, Malamani G et al. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension. Curr Ther Res Clin Exp 2001; 62: 68–78.Fogari R, Zoppi A, Malamani G et al. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension. Curr Ther Res Clin Exp 2001; 62: 68–78.Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor - independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res 2002; 90: 770–6.Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor - independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res 2002; 90: 770–6.Wolf P.A, Abbott R.D, Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.Wolf P.A, Abbott R.D, Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new - onset atrial fibrillation and subsequent stroke compared to atenolol: The LIFE Study. J Am Coll Cardiol 2005; 45: 712–9.Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new - onset atrial fibrillation and subsequent stroke compared to atenolol: The LIFE Study. J Am Coll Cardiol 2005; 45: 712–9.Devereux R.B, Bella J, Boman K et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10: 74–82.Devereux R.B, Bella J, Boman K et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10: 74–82.Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study. J Am Coll Cardiol 2005; 45: 705–11.Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study. J Am Coll Cardiol 2005; 45: 705–11.Olsen M.H, Wachtell K, Bella J.N et al. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy. Am J Hypertens 2005; 18: 1430–6.Olsen M.H, Wachtell K, Bella J.N et al. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy. Am J Hypertens 2005; 18: 1430–6.Ibsen H, Wachtell K, Olsen M.H et al., for the LIFE Substudy. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22: 1805–11.Ibsen H, Wachtell K, Olsen M.H et al., for the LIFE Substudy. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22: 1805–11.Kobel F, Gregorova I, Sonka J. Hyperuricaemia in hypertension. Lancet 1965; 1: 519–20.Kobel F, Gregorova I, Sonka J. Hyperuricaemia in hypertension. Lancet 1965; 1: 519–20.Kinsey D, Walther R, Sise H.S et al. Incidence of hyperuricaemia in 400 hypertensive patients. Circulation 1961; 24: 972–3.Kinsey D, Walther R, Sise H.S et al. Incidence of hyperuricaemia in 400 hypertensive patients. Circulation 1961; 24: 972–3.France L.V, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–54.France L.V, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–54.Hoieggen A, Alderman M.H, Kjeldsen S.E et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9.Hoieggen A, Alderman M.H, Kjeldsen S.E et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9.Sweet C.S, Bradstreet D.C, Berman R.S et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7 (12): 1035–40.Sweet C.S, Bradstreet D.C, Berman R.S et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7 (12): 1035–40.Burnier M, Hagmann M, Nussberger I et al. Short - term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25 (4p 1): 602–9.Burnier M, Hagmann M, Nussberger I et al. Short - term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25 (4p 1): 602–9.Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503–10.Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503–10.Webb A.J.S, Fischer U, Mehta Z, Rothwell P.M. Effects of antihypertensive - drug class on interindividual variation in BP and risk of stroke: a systematic review and meta - analysis. Lancet 2010; 375: 906–15.Webb A.J.S, Fischer U, Mehta Z, Rothwell P.M. Effects of antihypertensive - drug class on interindividual variation in BP and risk of stroke: a systematic review and meta - analysis. Lancet 2010; 375: 906–15.Rothwell P.M, Webb A.J.S. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011; 42: 2860–5.Rothwell P.M, Webb A.J.S. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011; 42: 2860–5.Rothwell P.M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.Rothwell P.M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.

The authors declare that there are no conflicts of interest present.